PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced
Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR
Mutations (A Pediatric MATCH Treatment Trial)
Research Question:
Does the drug LY3023414 help patients with cancers that have spread to other places
in the body and do not respond to treatment?
Basic Study Information
Purpose:
This phase II Pediatric MATCH trial studies how well PI3K/mTOR inhibitor LY3023414
works in
treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders
with TSC
or PI3K/MTOR mutations that have spread to other places in the body and have come
back or do
not respond to treatment. PI3K/mTOR inhibitor LY3023414 may stop the growth of cancer
cells
by blocking some of the enzymes needed for cell growth.
Location: University of Rochester
Study Contact Information
Phone: (585) 275-5830
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search